Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 11.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 94,779 shares of the company's stock after selling 12,482 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.19% of Prestige Consumer Healthcare worth $6,834,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Ariel Investments LLC boosted its position in shares of Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company's stock worth $195,204,000 after buying an additional 274,212 shares during the period. Victory Capital Management Inc. lifted its position in Prestige Consumer Healthcare by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company's stock worth $142,827,000 after acquiring an additional 171,357 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Prestige Consumer Healthcare by 19.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company's stock worth $113,570,000 after acquiring an additional 255,045 shares during the period. Congress Asset Management Co. grew its position in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company's stock valued at $62,375,000 after acquiring an additional 62,411 shares in the last quarter. Finally, Boston Trust Walden Corp purchased a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at approximately $41,785,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Up 1.2 %

Shares of NYSE:PBH traded up $0.97 during midday trading on Tuesday, reaching $84.25. The company had a trading volume of 375,918 shares, compared to its average volume of 251,839. The stock has a market capitalization of $4.16 billion, a P/E ratio of 20.50, a PEG ratio of 2.37 and a beta of 0.49. The stock's fifty day moving average price is $77.27 and its 200-day moving average price is $72.19. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. Prestige Consumer Healthcare Inc. has a one year low of $57.95 and a one year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. The business had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company's revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.07 EPS. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PBH has been the subject of several analyst reports. Jefferies Financial Group restated a "hold" rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday. Finally, DA Davidson restated a "buy" rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $85.25.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares of the company's stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock valued at $3,187,300 in the last quarter. Insiders own 1.60% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.